Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decline in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 47,300 shares, a decline of 23.1% from the December 15th total of 61,500 shares. Based on an average daily volume of 122,300 shares, the short-interest ratio is currently 0.4 days.

Hedge Funds Weigh In On Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Parkman Healthcare Partners LLC boosted its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 2.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 411,076 shares of the company’s stock after acquiring an additional 9,558 shares during the quarter. Parkman Healthcare Partners LLC owned 1.15% of Entera Bio worth $781,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 14.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Entera Bio in a research report on Monday, November 11th.

Entera Bio Stock Up 4.9 %

Shares of NASDAQ:ENTX traded up $0.11 during midday trading on Friday, reaching $2.34. 135,985 shares of the company traded hands, compared to its average volume of 206,778. Entera Bio has a 12 month low of $0.68 and a 12 month high of $3.35. The firm has a market capitalization of $83.73 million, a price-to-earnings ratio of -9.00 and a beta of 1.49. The firm’s fifty day moving average price is $2.04 and its two-hundred day moving average price is $1.87.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.